相似文献
1
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
Antimicrob Agents Chemother. 2002 Feb;46(2):522-4. doi: 10.1128/AAC.46.2.522-524.2002.
2
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2003 Aug;47(8):2606-14. doi: 10.1128/AAC.47.8.2606-2614.2003.
3
Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Int J Antimicrob Agents. 2002 Aug;20(2):93-9. doi: 10.1016/s0924-8579(02)00120-6.
4
Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2004 Apr;48(4):1215-21. doi: 10.1128/AAC.48.4.1215-1221.2004.
5
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 2001 Mar;39(3):195-7. doi: 10.1016/s0732-8893(01)00209-7.
6
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Clin Microbiol Infect. 2002 Jun;8(6):373-80. doi: 10.1046/j.1469-0691.2002.00405.x.
7
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
J Antimicrob Chemother. 2001 Jun;47(6):811-8. doi: 10.1093/jac/47.6.811.
8
Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Clin Microbiol Infect. 2002 Oct;8(10):680-3. doi: 10.1046/j.1469-0691.2002.00455.x.
9
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Antimicrob Agents Chemother. 2001 Mar;45(3):794-9. doi: 10.1128/AAC.45.3.794-799.2001.
10
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Antimicrob Agents Chemother. 2010 Feb;54(2):673-7. doi: 10.1128/AAC.01353-09. Epub 2009 Dec 14.
引用本文的文献
1
Does Chlorination Promote Antimicrobial Resistance in Waterborne Pathogens? Mechanistic Insight into Co-Resistance and Its Implication for Public Health.
Antibiotics (Basel). 2022 Apr 22;11(5):564. doi: 10.3390/antibiotics11050564.
2
Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance.
Molecules. 2020 Dec 1;25(23):5662. doi: 10.3390/molecules25235662.
3
Variation in Mutant Prevention Concentrations.
Front Microbiol. 2019 Jan 31;10:42. doi: 10.3389/fmicb.2019.00042. eCollection 2019.
4
Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.01971-17. Print 2018 Apr.
5
Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014).
PLoS One. 2016 May 26;11(5):e0154816. doi: 10.1371/journal.pone.0154816. eCollection 2016.
6
Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.
Nucleic Acids Res. 2016 Apr 20;44(7):3304-16. doi: 10.1093/nar/gkw161. Epub 2016 Mar 16.
7
Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
Antimicrob Agents Chemother. 2015 Apr;59(4):2398-404. doi: 10.1128/AAC.04659-14. Epub 2015 Feb 9.
8
Functional analysis of pneumococcal drug efflux pumps associates the MATE DinF transporter with quinolone susceptibility.
Antimicrob Agents Chemother. 2013 Jan;57(1):248-53. doi: 10.1128/AAC.01298-12. Epub 2012 Oct 31.
9
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Antimicrob Agents Chemother. 2010 Feb;54(2):673-7. doi: 10.1128/AAC.01353-09. Epub 2009 Dec 14.
10
Quinolones: action and resistance updated.
Curr Top Med Chem. 2009;9(11):981-98. doi: 10.2174/156802609789630947.
本文引用的文献
1
Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.
Antimicrob Agents Chemother. 2001 Oct;45(10):2703-9. doi: 10.1128/AAC.45.10.2703-2709.2001.
2
Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States.
Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S187-92. doi: 10.1086/321847.
3
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
J Infect Dis. 2001 Sep 15;184(6):794-8. doi: 10.1086/323086. Epub 2001 Aug 9.
4
Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2001 Jun;45(6):1649-53. doi: 10.1128/AAC.45.6.1649-1653.2001.
5
Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis.
Antimicrob Agents Chemother. 2001 Apr;45(4):1037-42. doi: 10.1128/AAC.45.4.1037-1042.2001.
6
Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2001 Feb;45(2):433-8. doi: 10.1128/AAC.45.2.433-438.2001.
7
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
J Antimicrob Chemother. 2000 May;45(5):583-90. doi: 10.1093/jac/45.5.583.
8
Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
Antimicrob Agents Chemother. 1999 Dec;43(12):2969-74. doi: 10.1128/AAC.43.12.2969.
9
Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.
Antimicrob Agents Chemother. 1999 Nov;43(11):2793-7. doi: 10.1128/AAC.43.11.2793.
10
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Antimicrob Agents Chemother. 1999 Aug;43(8):2000-4. doi: 10.1128/AAC.43.8.2000.
Zotero 插件